AP
SAGE

AHL Partners’s Sage Therapeutics SAGE Stock Holding History

AHL Partners’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,106
Closed -$443K – 1353
2017
Q3 		$443K Buy
+7,106
New +$558K 0.01% 1082
2016
Q4 		– Sell
-10,712
Closed -$493K – 1169
2016
Q3 		$493K Buy
+10,712
New +$436K 0.02% 842

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

AHL Partners's SAGE Position: Q4 2017 in Review

AHL Partners sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 7,106 shares — an estimated $443K sold.

AHL Partners first reported a position in SAGE in Q3 2016 and held it in 2 quarters. The position peaked at $493K in Q3 2016. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

  • AHL Partners reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 7,106 Sage Therapeutics shares in Q4 2017, an estimated $443K.
  • AHL Partners first reported a position in Sage Therapeutics in Q3 2016 and held it in 2 quarters.
  • AHL Partners's Sage Therapeutics position peaked at $493K in Q3 2016.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.